204 completed, 75 unknown, 67 recruiting, 61 terminated. 472 Phase 2, 77 Phase 1, 35 Phase 3.
Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2027-01-30 | 2026-11-05 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia Hetrombopag and recombinant human thrombopoietin, Recombinant Human Thrombopoietin - Thrombocytopenia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 96 | 2026-12-01 | 2026-11-12 |
| Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 90 | 2026-12-01 | 2026-11-12 |
| Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia Luspatercept, Pacritinib - Myelofibrosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 50 | 2026-12-01 | 2026-11-13 |
| Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias Avatrombopag - Thrombocytopenia | Phase 2 | Not yet recruiting | University of Virginia | 26 | 2026-11-01 | 2026-10-26 |
| Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Henan University of Science and Technology | 87 | 2026-11-01 | 2026-09-21 |
| TGD001 Treatment in Thrombotic Microangiopathies TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | TargED Biopharmaceuticals B.V. | 70 | 2026-10-25 | 2026-11-12 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 164 | 2026-08-04 | 2026-11-06 |
| HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB ALN-6400 - Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) | Phase 2 | Recruiting | Alnylam Pharmaceuticals | 24 | 2026-07-30 | 2026-11-13 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles - Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT) | Phase 2 | Recruiting | Fudan University | 126 | 2026-07-16 | 2026-11-02 |
| Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. Nplate, NaCl %0.9 - Chirurgical Intervention, Thrombocytopaenia | Phase 2 | Recruiting | Nantes University Hospital | 142 | 2026-07-16 | 2026-10-28 |
| Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP Eltrombopag - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-07-10 | 2026-07-07 |
| TPO-RA Plus Baricitinib vs. TPO-RA for ITP Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-07-01 | 2026-06-25 |
| Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-26 | 2026-10-15 |
Showing 20 of 472. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (168) · Thrombocytopenia (158) · Thrombocythemia, Essential (88) · Polycythemia Vera (79) · Primary Myelofibrosis (78) · Myeloproliferative Disorders (64) · Myelodysplastic Syndromes (44) · Leukemia, Myeloid, Acute (40) · Leukemia (39) · Leukemia, Myelomonocytic, Chronic (35) · Leukemia, Lymphocytic, Chronic, B-Cell (33) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (30) · Multiple Myeloma (29) · Lymphoma, Non-Hodgkin (25) · Leukemia, Myeloid, Accelerated Phase (23)
Hemic and Lymphatic Diseases (472) · Hematologic Diseases (457) · Cytopenia (348) · Blood Coagulation Disorders (293) · Hemorrhagic Disorders (285) · Pathologic Processes (271) · Pathological Conditions, Signs and Symptoms (271) · Immune System Diseases (238) · Thrombotic Microangiopathies (196) · Thrombocytopenia (194) · Hemorrhage (188) · Signs and Symptoms (188) · Skin Manifestations (186) · Purpura (183)
eltrombopag (52) · romiplostim (29) · Dexamethasone (27) · Cyclophosphamide (24) · Rituximab (23) · fludarabine phosphate (22) · Peripheral Blood Stem Cell Transplantation (19) · Busulfan (17) · avatrombopag (17) · Cyclosporine (16) · Tacrolimus (14) · ruxolitinib (13) · Danazol (12) · Whole-Body Irradiation (12) · Methotrexate (11)
Peking University People's Hospital (43) · Institute of Hematology & Blood Diseases Hospital, China (27) · M.D. Anderson Cancer Center (14) · National Heart, Lung, and Blood Institute (NHLBI) (14) · Shandong University (14) · Fred Hutchinson Cancer Center (12) · Novartis Pharmaceuticals (11) · Amgen (10) · GlaxoSmithKline (8) · Alexion Pharmaceuticals, Inc. (7) · Weill Medical College of Cornell University (7) · National Cancer Institute (NCI) (6) · Mayo Clinic (5) · Memorial Sloan Kettering Cancer Center (5) · Peking Union Medical College Hospital (5)
United States (213) · China (121) · United Kingdom (52) · Germany (49) · Italy (49) · France (46) · Spain (32) · Canada (28) · Australia (25) · Poland (25) · Austria (17) · Belgium (17) · Netherlands (17) · South Korea (15) · Czechia (12)
Lei Zhang, MD (15) · Xiao-Hui Zhang, MD (10) · Xiaohui Zhang, MD (8) · Ruben A. Mesa, MD (4) · Xiaohui Zhang (4) · Alessandro Rambaldi, MD (3) · Cynthia E Dunbar, M.D. (3) · David Gomez-Almaguer, MD (3) · James B Bussel, M.D. (3) · Lei Zhang, M.D. (3)
PMID 33783815, PMID 23738544, PMID 24802773, PMID 19846889, PMID 29958797, PMID 34724566, PMID 19005182, PMID 22067384, PMID 23470153, PMID 24802775, PMID 27658437, PMID 29419434, PMID 29674506, PMID 30992268, PMID 32499241, PMID 35030255, PMID 10758304, PMID 11468154, PMID 12353309, PMID 12506176, PMID 15254053, PMID 15389904, PMID 17170128, PMID 17825602, PMID 18046028, PMID 18156492, PMID 18195173, PMID 18463354, PMID 19096013, PMID 19144680, PMID 19208097, PMID 19231632, PMID 19446902, PMID 19731307, PMID 19841031, PMID 20058208, PMID 20110050, PMID 20576011, PMID 20651074, PMID 20841509, PMID 20843246, PMID 20844233, PMID 2110385, PMID 21106014, PMID 21266777, PMID 21636861, PMID 21833452, PMID 21877169, PMID 22223819, PMID 22475545
2018 (7), 2023 (6), 2014 (4), P30CA015083 (4), 2019 (3), P01CA108671 (3), P30CA015704 (3), 2025 (2), P01CA015396 (2), P01CA018029 (2), P30CA006973 (2), P30CA016672 (2), 2004 (1), 2008 (1), 2016 (1)